Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:mythological_figure
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Ciba-Geigy
|
| gptkbp:activities |
inhibits microtubule synthesis
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:1971
gptkb:FDA |
| gptkbp:brand |
Vermox
|
| gptkbp:clinical_trial |
Phase IV
elderly patients pediatric patients adult patients immunocompromised patients |
| gptkbp:color |
gptkb:white
|
| gptkbp:contraindication |
pregnancy
lactation |
| gptkbp:developed_by |
gptkb:Johnson_&_Johnson
|
| gptkbp:dissolved |
poorly soluble in water
|
| gptkbp:dosage_form |
gptkb:tablet
suspension 100 mg twice daily 500 mg single dose for some infections |
| gptkbp:excretion |
urine
|
| gptkbp:flavor |
gptkb:beer
|
| https://www.w3.org/2000/01/rdf-schema#label |
Mebendazole
|
| gptkbp:ingredients |
C16 H19 N3 O3
|
| gptkbp:interacts_with |
gptkb:phenytoin
gptkb:phenobarbital gptkb:warfarin |
| gptkbp:invention |
generic available since 1982
patented until 1981 |
| gptkbp:is_atype_of |
P02 C A01
|
| gptkbp:is_available_in |
tablets
suspension |
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
treating parasitic worm infections
|
| gptkbp:level |
5.5
|
| gptkbp:lifespan |
2.5 to 5 hours
|
| gptkbp:manager |
oral
|
| gptkbp:metabolism |
liver
|
| gptkbp:research_areas |
pharmacology
tropical medicine parasitology |
| gptkbp:safety_features |
Category C
|
| gptkbp:side_effect |
dizziness
headache nausea abdominal pain allergic reactions diarrhea liver toxicity skin rash |
| gptkbp:storage |
room temperature
|
| gptkbp:treatment |
ascariasis
strongyloidiasis enterobiasis hookworm infection whipworm infection |
| gptkbp:type_of |
31431-39-7
|